Maintaining Neutral: Hold Rating on Zymeworks Amidst Preclinical Progress and Upcoming Catalysts
HC Wainwright & Co. Reiterates Neutral on Zymeworks, Maintains $10 Price Target
Zymeworks Analyst Ratings
Zymeworks' Hold Rating Amidst Promising Data and Competitive HER2+ GEA Treatment Landscape
Stifel Maintains Zymeworks(ZYME.US) With Buy Rating, Maintains Target Price $21
Stifel Nicolaus Keeps Their Buy Rating on Zymeworks (ZYME)
Buy Rating on Zymeworks Stock Amid Anticipated Zani Approval and Strategic Capital Allocation
Analysts Conflicted on These Healthcare Names: Henry Schein (HSIC), Zymeworks (ZYME) and Rocket Pharmaceuticals (RCKT)
Zymeworks Analyst Ratings
Zymeworks (ZYME) Receives a Buy From Stifel Nicolaus
Stifel Maintains Zymeworks(ZYME.US) With Buy Rating, Raises Target Price to $21
Maintaining Hold on Zymeworks: A Balanced View of Financials and Future Catalysts
Zymeworks Analyst Ratings
Zymeworks Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Zymeworks, Maintains $10 Price Target
Stifel Nicolaus Reaffirms Their Buy Rating on Zymeworks (ZYME)
Zymeworks Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Zymeworks, Maintains $10 Price Target
Citi: Maintains the Zymeworks (ZYME.US) rating, adjusted from buy to buy rating, and adjusted the target price from $17.00 to $16.00.
Zymeworks Analyst Ratings